ASH25 Day 1: Don’t Miss The Highlights
The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.
It aims to bring together hematology professionals from across the globe.
Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.
Find the highlights from Day 1
”API-CAT Post-hoc of Isabelle Mahe at ASH25
Predictors of clinically relevant bleeding during extended apixaban for cancer-associated VTE:
- Anemia/Thrombocytopenia high risk (HR 1.93)
- Age ≥75 ↑ (1.51)
- Index PE – high (1.47)
- Male sex – high (1.38)
Findings consistent across cancer types.
”
”Wonderful start to the ASH2025 meeting at American Society of Hematology National Meeting.
Day 1 was dedicated for deep study of bleeding disorders in humans and novel science that is changing how we treat patients in real world at the Octapharma Factor academy!
Great speakers , great Science setting the tone for a great hematology meeting over the next few days.
Claudio Sandoval, Robert Sidonio
”
”ASH25 “decoding DDX41 mutant HR-MDS and AML”
Conclusion:
1. Not every DDX41-mutant HR-MDS/AML responds well to venetoclax plus HMA.
2. no survival difference between pathogenic vs VUS variants.
3. Splicing-factor co-mutations predicted worse outcomes, while allo-HCT trended better.
Highlights need for larger cohorts to refine predictors.
”
”ASH25 Stop today by our poster 2712 “Interim analysis of a non-interventional prospective study to assess the impact on Patient’s well-being of fixed-time duration (FTD) and continuous oral regimens for newly diagnosed and R/R CLL in routine clinical practice in Spain
”
”Casulo et al: A-HIPI in S1826
– compared with IPS, A-HIPI superior
– Better prognostication: HR 2.4 for pts above median A-HIPI
– Better discrimiation: C-stat 0.627 (vs 0.591)
– Held for both regimens
– best prog 18-40y
Still not a perfect score, but better!
”
”Great presentation by Amer Zeidan of Bexmarilimab- 1st in class Clever-1 Ab- w/ Aza in 1L and R/R HR- MDS w/enrichment for TP53m.
Impressive data both in 1L and R/R MDS.
Privilege to enroll on this study at UNC Lineberger and looking forward to next steps.
”
”Was hopeful reduction in days of AZA (AZA5) with VEN would hold up.
Per VenAza-5S not yet.
cCR 51.1% (*VIALE-A 66.4%)
mOS 9.8mo (*14.7mo)
Gr.3 FN 13% (*30%)
Awaiting the SAL propensity matched analysis but for now we’re stuck with AZA7.
”
”Genuinely excited to be finally able to fully share the first major output from the MEASURE consortium at ASH25 – the largest cohort of paired tumor and remission WGS from patients with AML
Read the full article.
”
”Are Ven+Gilt-based regimens safe and effective for FLT3m AML in the real-world setting?
Stop at our poster No 1679: CR+CRp 82%, ORR 95%, mOS 25mo in ND + R/R pts. 40% bridged to alloSCT.
No signals of excessive toxicity or prolonged myelosupression
”
”All-star expert line-up at the Treatment Advances in HR-MDS session at ASH2025 discussing HMA+Ven in frontline HR-MDS and t-MDS.
Unfortunately no improvement in OS when compared with HMA.
Future research likely to identify subgroups that will benefit most from this combination.
”
”Bispecific antibodies as frontline for older adults w/DLBCL at ASH2025
My conclusions:
BiTEs monotherapy ≈ R-miniCHOP
Adding drugs to BiTEs = higher efficacy and AEs
Geriatric assessment and evaluation of anthracycline eligibility are mandatory to apply best approach!
”
More from ASH25 featured in Hemostasis Today.
-
Aug 12, 2026, 08:16Chengyong Yang: Can Plasma Reveal Cell Specific Signals
-
Aug 12, 2026, 07:49Alan Dursun: Phnom Penh, Cambodia – Part 3 – Turning Partnership into Action
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 06:01Sophie He: Exploring Manufacturing Scalability and Cell Separation
-
Aug 12, 2026, 05:54Yuan Goessi: One Bleed Is One Too Many for a Lifetime of Haemophilia A